Form 4: Barinthus Biotherapeutics Chief Medical Officer Granted Stock Options

Leon Hooftman, Chief Medical Officer of Barinthus Biotherapeutics plc, was granted options to purchase 195,166 ordinary shares on June 3, 2024.

Summary

• On June 3, 2024, Leon Hooftman, the Chief Medical Officer of Barinthus Biotherapeutics plc, was granted options to purchase 195,166 ordinary shares.
• The exercise price of these options is $2.
• The options vest in three equal annual installments, starting on June 3, 2025.
• The options expire on June 3, 2034.
• Following this transaction, Hooftman directly owns options for 195,166 ordinary shares.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and terms of the grant are typical for a Chief Medical Officer role in a company of Barinthus Biotherapeutics' size and stage.

Comparison to Industry Standards

• Stock option grants for CMOs in similar biotech companies typically range from 0.1% to 0.5% of outstanding shares, depending on the company's market capitalization and stage of development.
• Vesting schedules of three to four years with annual or quarterly vesting are standard practice.
• Exercise prices are usually set at or above the fair market value of the stock on the grant date.

Stakeholder Impact

• Shareholders: The option grant aligns the executive's interests with increasing shareholder value.
• Employees: The grant may have a positive impact on employee morale as it signals confidence in the company's future.

Key Dates